Refractory primary mediastinal large B-cell lymphoma
Clinical trials for Refractory primary mediastinal large B-cell lymphoma explained in plain language.
Never miss a new study
Get alerted when new Refractory primary mediastinal large B-cell lymphoma trials appear
Sign up with your email to follow new studies for Refractory primary mediastinal large B-cell lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug may help more patients get Life-Saving CAR-T therapy
Disease control Recruiting nowThis study tests whether giving the drug odronextamab before CAR-T cell therapy can help control aggressive large B-cell lymphomas that have returned or not responded to prior treatment. About 27 adults will receive odronextamab to slow disease progression and increase the chance…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for tough lymphoma: drug combo aims to boost transplant success
Disease control Recruiting nowThis phase 2 trial tests whether adding the immunotherapy epcoritamab to standard chemo (R-GemOx) before an autologous stem cell transplant can improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolls 43 adults whose lymphom…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug duo aims to outsmart tough lymphoma
Disease control Recruiting nowThis trial tests a combination of two drugs, epcoritamab and ibrutinib, for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. Epcoritamab helps immune cells attack lymphoma cells, while ibrutinib blocks signals that help cancer ce…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase 1/2 • Sponsor: Yazeed Sawalha • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New combo therapy aims to stop aggressive lymphoma relapse
Disease control Recruiting nowThis study tests whether adding a drug called golcadomide after standard CAR T-cell therapy can prevent aggressive large B-cell lymphoma from returning in patients at high risk of relapse. About 65 adults will receive golcadomide for 24 weeks starting 5 days after their CAR T-cel…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase 2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New combo may help more lymphoma patients reach potentially curative CAR-T
Disease control Recruiting nowThis study tests whether giving two drugs, golcadomide and rituximab, before CAR-T cell therapy can help control aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The goal is to keep the disease in check so more patients can qualify for…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC